{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-315574","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.827860+00:00","generated_at":"2026-06-28T15:42:20.641849+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Akebia Therapeutics elects Ron Frieson as independent Class I director, effective Nov 1, 2021","bullets":["Board expanded from 8 to 9 directors; Frieson's term expires at 2024 annual meeting.","Frieson determined independent per Nasdaq rules; no related-party transactions.","Entitled to annual cash retainer of $45,000, equity grants of 20,100 options and 13,700 RSUs.","Received initial director grant: option for 80,200 shares at $3.13 (Nov 1 closing price).","Standard indemnification agreement as per Company's non-employee director program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-315574","json":"https://secwatch.observer/filing/0001193125-21-315574.json","markdown":"https://secwatch.observer/filing/0001193125-21-315574.md","text":"https://secwatch.observer/filing/0001193125-21-315574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000119312521315574/0001193125-21-315574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000119312521315574/d247159d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:42:20.641849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b21fb906fd","claim":"Ron Frieson was elected as Class I director at Akebia Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, increased the Board’s size from eight to nine directors and elected Ron Frieson as a Class I director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000119312521315574/0001193125-21-315574-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}